A5049111253- Botulinum Toxin and Related Neurological Disorders
- Stroke Rehabilitation and Recovery
- Cerebral Palsy and Movement Disorders
- Neurological disorders and treatments
- Parkinson's Disease Mechanisms and Treatments
- Hereditary Neurological Disorders
- Parkinson's Disease and Spinal Disorders
- Employment and Welfare Studies
- Musculoskeletal pain and rehabilitation
- Muscle activation and electromyography studies
- Acute Ischemic Stroke Management
- Health Systems, Economic Evaluations, Quality of Life
- Neurogenetic and Muscular Disorders Research
- Social Policy and Reform Studies
- EEG and Brain-Computer Interfaces
- Retirement, Disability, and Employment
- Workplace Health and Well-being
- Adolescent and Pediatric Healthcare
- Healthcare innovation and challenges
- Bipolar Disorder and Treatment
- Neurological Disorders and Treatments
- Meta-analysis and systematic reviews
- Obsessive-Compulsive Spectrum Disorders
- Intramuscular injections and effects
- Connective tissue disorders research
Austrian Competence Centre of Food Safety
2013-2025
Swiss Paraplegic Center
2022
Universität für Weiterbildung Krems
2013-2022
Tirol Kliniken
2022
MED-EL (Austria)
2022
Innsbruck Medical University
2022
Universität Innsbruck
2022
Kepler Universitätsklinikum
2022
Paracelsus Medical University
2022
VASCage
2022
Abstract Introduction Neurogenic dysphagia defines swallowing disorders caused by diseases of the central and peripheral nervous system, neuromuscular transmission, or muscles. is one most common at same time dangerous symptoms many neurological diseases. Its important sequelae include aspiration pneumonia, malnutrition dehydration, affected patients more often require long-term care are exposed to an increased mortality. Based on a systematic pubmed research related original papers, review...
Abstract Botulinum toxin (BT) therapy is a complex and highly individualised defined by treatment algorithms injection schemes describing its target muscles their dosing. Various consensus guidelines have tried to standardise improve BT therapy. We wanted update by: (1) Acknowledging recent advances of algorithms. (2) Basing dosing tables on statistical analyses real-life data 1831 injections in 36 different 420 dystonia patients 1593 31 240 spasticity patients. (3) Providing more detailed...
Objective To describe real-life practice and person-centred outcomes in the treatment of poststroke upper limb spasticity with botulinum toxin A (BoNT-A). Design Observational, prospective study. Setting 84 secondary care centres 22 countries. Participants 456 adults (≥18 years) treated one cycle BoNT-A. Methods/outcomes Muscle selection, BoNT-A preparation, injection technique timing follow-up were conducted according to routine for each centre. Primary outcome: achievement patient's...
To better understand patient perspectives on the life impact of spasticity.Global Internet survey (April 2014-May 2015) 281 people living with spasticity.Respondents indicated that spasticity has a broad their daily-life: 72% reported quality life, 44% loss independence and depression. Most respondents (64%) were cared for by family members, whom half had stopped working or reduced hours. Overall, 45% dissatisfaction information provided at diagnosis; main reasons "not enough information"...
Pain reduction is a common goal of the treatment upper limb spasticity with botulinum toxin (BoNT-A). ULIS-III was large international, observational, longitudinal study (N = 953) conducted in real-life clinical practice over two years. In this secondary post hoc analysis, we examine whether goals for pain were met repeated injection cycles. We report serial changes severity and explore predictors frequency. Patients selected if primary/secondary at least one cycle (n 438/953). They assessed...
Objectives This article provides an overview of the Upper Limb International Spasticity (ULIS) programme, which aims to develop a common core dataset for evaluation real-life practice and outcomes in treatment upper-limb spasticity with botulinum toxin A (BoNT-A). Here we present study protocol ULIS-II, large, international cohort study, describe rationale steps ensure validity goal attainment scaling (GAS) as primary outcome measure. Methods analysis design An international, multicentre,...
Background: Persons with chronic diseases (PwCDs) often experience work-related problems, and innovative actions to improve their participation in the labor market are needed. In frame of European (EU) Pathways Project, aim study is compare existing strategies (policies, systems, services) for professional (re-)integration PwCDs mental health conditions available at both national level between different welfare models: Scandinavian, Continental, Anglo-Saxon, Mediterranean, “Post-Communist”....
To assess the longitudinal effects of integrated spasticity management incorporating repeated cycles botulinum toxin A type (BoNT-A) over 2 years.The Upper Limb International Spasticity study was a prospective, observational, cohort following adult patients years upper-limb including repeat treatment (any commercially-available product).A total 1,004 participants from 14 countries were enrolled, which 953 underwent ≥ 1 BoNT-A injection cycle (median 4 cycles) and had goal attainment scaling...
Describe the rationale and protocol for Upper Limb International Spasticity (ULIS)-III study, which aims to evaluate impact of integrated spasticity management, involving multiple botulinum toxin A (BoNT-A) injection cycles concomitant therapies, on patient-centred goal attainment. Outline novel outcome assessment methods ULIS-III report initial evaluation data from setting in early stages study.Large international longitudinal cohort study upper limb including BoNT-A.ULIS-III is a 2-year...
Background: Recent studies of botulinum toxin for post-stroke spasticity indicate potential benefits early treatment (i. e., first 6 months) in terms developing hypertonicity, pain and passive function limitations. This non-interventional, longitudinal study aimed to assess the impact disease duration on effectiveness abobotulinumtoxinA upper limb spasticity. Methods: The early-BIRD (NCT01840475) was conducted between February 2013 2018 43 centers across Germany, France, Austria, Netherlands...
In this post-hoc analysis of the ULIS-II study, we investigated factors influencing person-centred goal setting and achievement following botulinum toxin-A (BoNT-A) treatment in 456 adults with post-stroke upper limb spasticity (ULS). Patients primary goals categorised as passive function had greater motor impairment (p < 0.001), contractures (soft tissue shortening [STS]) = 0.006) 0.02) than those other types. active less (0.0001), contracture 0.0001), 0.001) shorter time since stroke...
Abstract Background Hereditary spastic paraplegia (HSP) is a group of inherited disorders characterized by progressive paresis the lower limbs. Treatment often focused on reducing spasticity and its physical consequences. To better address individual patients’ needs, we investigated broad range experienced complaints, activity limitations, loss motor capacities in pure HSP. In addition, aimed to identify patient characteristics that are associated with increased fall risk and/or reduced...
To describe the utility of a structured approach to assessing effectiveness following injection with botulinum toxin-A alongside physical therapies, within first cycle Upper Limb International Spasticity-III (ULIS-III) study.ULIS-III (registered at clinicaltrials.gov as NCT02454803) is large international, observation-al, longitudinal study adults treated for upper-limb spasticity. It introduces novel methods evaluation person-centred goal attainment targeted standardized outcome measures:...
Background: To explore predictors of treatment response in adults receiving botulinumtoxin-A (BoNT-A) for upper limb spasticity (ULS) and to describe the association between concomitant medication, professional physical therapy, quality life (QoL). Methods: This was a secondary analysis longitudinal Upper Limb International Spasticity study (ULIS-III) data set. Eligible patients were receiving/initiating BoNT-A ULS clinical practice. The goal attainment scaling (GAS) T score change ≥10...
The increase in resistance to passive muscle stretch a paretic limb due an upper motor neurone lesion is often referred as spasticity. However, this terminology inaccurate and does not take into account the complex pathogenesis of condition or describe factors that contribute clinically observed changes tone. In report we propose alternative explain reasons for doing so.
The increasing prevalence of chronic diseases among the European working age population, as well implications for individual and societal level, underline need policy guidelines targeting effective inclusion persons with in workplace. aim present paper was to explore perspectives National-level stakeholders on existing strategies work re-integration diseases, provide guidelines. A highly-structured interview protocol distributed 58 National level (policy makers, professionals employers) from...
Abstract Background We evaluated quality of life among subjects with upper- and lower-limb spasticity who received escalating doses incobotulinumtoxinA (total body up to 800 U) in the prospective, single-arm, dose-titration TOWER study. Methods In this exploratory trial, ( N = 155; 18–80 years age) due cerebral causes were deemed require total U three consecutive injection cycles (400, 600, U), each 12 16 weeks’ follow-up. QoL was assessed using EuroQol 5-dimensions questionnaire,...
Spastic paresis can arise from a variety of conditions, including stroke, spinal cord injury, multiple sclerosis, cerebral palsy, traumatic brain injury and hereditary spastic paraplegia. It is associated with muscle contracture, stiffness pain, lead to segmental deformity. The positive, negative biomechanical symptoms significantly affect patients℉ quality life, by affecting their ability perform normal activities. This paper – based on the content global spasticity interdisciplinary...
Abstract Background We aimed to identify healthcare needs, expectations, utilization, and the experienced treatment effects in a population of Dutch patients with hereditary spastic paraplegia (HSP). Methods distributed an online questionnaire among 194 adult persons HSP Netherlands, which 166 returned fully completed version. After applying predefined exclusion criteria, 109 questionnaires from pure were analysed. Results Healthcare needs expectations primarily focused on relief muscle...
Botulinum toxin is a well-established treatment for number of conditions involving muscle hyperactivity, such as focal dystonia and spastic paresis. However, current injection practice not standardized there clear need structured training. An international group experts in the management patients with cervical (CD) paresis created steering committee (SC). For each therapeutic area, SC developed core slide set on best practice, based literature. International sites expertise were identified...